Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
16 Septembre 2022 - 3:00PM
via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company)
( NASDAQ , TSX : NVCN) today announced that its
management team will be participating in the LSI Europe 2022
Emerging MedTech Summit in Hertfordshire, United Kingdom on
September 21-24, 2022.
Neovasc’s President and Chief Executive Officer, Fred Colen,
will be presenting at 11:10 am BST / 6:10 am ET on September 23,
2022. Interested parties may view a live stream of Mr. Colen’s
presentation by registering on the LSI website here. An email
with login instructions will be sent after registering.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops,
manufactures, and markets products for the rapidly growing
cardiovascular marketplace. Its products include Reducer, for the
treatment of refractory angina, which is under clinical
investigation in the United States and has been commercially
available in Europe since 2015, and Tiara™ for the transcatheter
treatment of mitral valve disease, which is currently under
clinical investigation in the United States, Canada, Israel and
Europe. For more information, visit: www.neovasc.com.
Forward-Looking Statement DisclaimerCertain statements in this
news release contain forward-looking statements within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995 and
applicable Canadian securities laws that may not be based on
historical fact. When used herein, the words expect, anticipate,
estimate, may, will, should, intend, believe, and similar
expressions, are intended to identify forward-looking statements.
Forward-looking statements may involve, but are not limited to, the
Company’s participation at the 2022 Sidoti & Co. Summer Small
Cap Virtual Investor Conference and the timing thereof and the
growing cardiovascular marketplace. Forward-looking statements are
based on estimates and assumptions made by the Company in light of
its experience and its perception of historical trends, current
conditions and expected future developments, as well as other
factors that the Company believes are appropriate in the
circumstances. Many factors could cause the Company’s actual
results, performance or achievements to differ materially from
those expressed or implied by the forward-looking statements,
including those described in the Risk Factors section of the
Company’s Annual Report on Form 20-F and in the Management’s
Discussion and Analysis for the three and six months ended June 30,
2022 (copies of which may be obtained
at www.sedar.com or www.sec.gov ). These
factors should be considered carefully, and readers should not
place undue reliance on the Company’s forward-looking statements.
The Company has no intention and undertakes no obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contacts
InvestorsMike CavanaughICR WestwickePhone:
+1.617.877.9641Mike.Cavanaugh@westwicke.com
MediaSean LeousICR WestwickePhone:
+1.646.866.4012Sean.Leous@westwicke.com
Neovasc (NASDAQ:NVCN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Neovasc (NASDAQ:NVCN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024